News & Stories

See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.

Kayleena Speakman Joins The CMT Research Foundation as Communications Manager

Jan 4, 2024 | News, Press Releases

Kayleena Speakman has joined The CMT Research Foundation, a patient-led, non-profit focused on delivering treatments and cures for CMT as Communications Manager responsible for emails, blogs, social media posts and opinion pieces for the CMT community, donors,...

An Extraordinary Year and the Road Ahead

Jan 3, 2024 | News

As we begin 2024, I want to take a look back and celebrate the extraordinary year we had at the CMT Research Foundation. Since 2018, CMTRF has had an outsized impact on inspiring drug hunters to work on developing therapeutics for CMT and establishing itself as a key...

Update from the Novartis CMT1A Development Team

Oct 29, 2023 | About CMT, Drug Development, News

As you know, the CMT Research Foundation is proud to have introduced DTx leadership to Charcot-Marie-Tooth disease in 2019. We funded their first work in CMT to demonstrate the FALCON platform's potential to deliver a drug to the Schwann cells. And from there, the...

Arthur Suckow, former Co-founder and Chief Executive Officer of DTx Pharma, Joins CMT Research Foundation Board of Directors

Oct 3, 2023 | News, Press Releases

ATLANTA (October 3, 2023) CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced that Arthur Suckow, Ph.D. former Co-founder and Chief Executive Officer of DTx...

Another Asset with Potential to Treat Charcot-Marie-Tooth has been Acquired by Pharma

Sep 26, 2023 | News, Press Releases

An asset that is being tested in CMT4B1 underwritten by the CMT Research Foundation has been licensed by AcuraStem to Takeda for approximately $580 million. The exclusive, worldwide license will enable Takeda to develop and commercialize AcuraStem's PIKFYVE targeted...

W. David Arnold, MD Joins CMT Research Foundation Scientific Advisory Board

Aug 14, 2023 | News, Press Releases

ATLANTA (August 14, 2023) CMT Research Foundation (CMTRF), a patient-led, non-profit focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced that Dr. W. David (Dave) Arnold has joined the Foundation’s Scientific Advisory...

DTx Pharma

May 8, 2023 | About CMT, News

We are pleased share this story that published on May 3: https://patientworthy.com/2023/05/03/dtx-pharma-developing-cmt1a-rna-therapeutics/ One of the early programs CMTRF funded was DTx, a young company that had developed a new platform for RNA therapeutics. DTx was...

The CMT Research Foundation (CMTRF) Joins the European CMT Federation (ECMTF)

Mar 28, 2023 | News, Press Releases

The CMTRF is happy to announce that they are joining the ECMTF, a non-profit organization grouping European and worldwide national associations supporting people affected by the Charcot-Marie-Tooth (CMT) disease or neuromuscular disorders. One of the primary goals of...

CMT Research Foundation Collaborates with Augustine Therapeutics on New Potential Therapy for Charcot-Marie-Tooth Disease

Mar 2, 2023 | CMTRF Funded Research, News, Press Releases, Research News

ATLANTA (March 2, 2023) The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, is pleased to announce a collaboration with Augustine Therapeutics, a Belgian pharmaceutical company...

‘Amazon Smile’ Program Discontinued

Feb 21, 2023 | News

On February 20th, 2023, Amazon ended their Amazon Smile Charity Program. Thank you to the nearly 200 people who supported the CMT Research Foundation through this program. In total, the community was able to raise:Interested in finding a new way to make a difference,...